Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment

Abstract In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the results of two-phase III double-blind clinical trials have been less than expected, tocilizumab has a real remaining potential to treat selected critical cases of COVID-19 beyond clinical trials until more data are revealed. On the contrary, remdesivir, though its FDA approval, and favipiravir are least likely to benefit COVID-19 patients. Moreover, we recommend that the RECOVERY dexamethasone should only be considered for critical hospitalized COVID-19 patients and we urge physicians in developing countries to avoid using it in mild-moderate COVID-19 cases. Finally, we recommend considering a personalized risk-benefit ratio before a decision is made using any of these drugs..

Media Type:

Electronic Article

Year of Publication:

2021

Publication:

2021

Contained In:

To Main Record - volume:3

Contained In:

SN comprehensive clinical medicine - 3(2021), 4 vom: 19. Feb., Seite 919-923

Language:

English

Contributors:

Kelleni, Mina T. [Author]

Links:

Volltext [Lizenzpflichtig]

Keywords:

COVID-19
Dexamethasone
Favipiravir
Remdesivir
Tocilizumab

doi:

10.1007/s42399-021-00824-4

PPN (Catalogue-ID):

SPR04363429X